Sensyne Health PLC (LON:SENS) has signed a £470,000 agreement with the Department of Health & Social Care (DHSC).
Sensyne, a specialist in artificial intelligence technology in a healthcare context, will participate in the second stage of a pilot study of its MagnifEye technology for use with COVID-19 lateral flow diagnostic tests.
The agreement follows on from Sensyne’s exclusive licence and development agreement with Excalibur Healthcare Services, announced last month, for the use of MagnifEye with Excalibur's proprietary lateral flow rapid COVID-19 diagnostic tests.
READ Sensyne Health shares rise on COVID-19 test partnership with Excalibur
"We are delighted to be working with the Department of Health & Social Care and Excalibur and are happy to be able to contribute to the UK's COVID-19 testing programme by providing our MagnifEye technology for use with lateral flow diagnostic tests and look forward to the results of this pilot study," said Paul Drayson, the chief executive of Sensyne Health.
OUR DISCOVERY SCIENCES WORK – Early risk assessment for COVID-19 patients from emergency department data using machine learning. Find out more: https://t.co/i52S0Qeea0 @nresearchnews #SensyneHealth #Covid #ML #Data #PatientCare pic.twitter.com/VqNcdcZusY
— Sensyne Health (@SensyneHealth) March 9, 2021